- Active not recruitingPHASE3
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
This study compares a new treatment, 177Lu-PSMA-617, with standard hormone therapy for advanced prostate cancer. It aims to see if the new treatment helps people live longer or keeps their cancer in check for longer, for those who haven't had certain chemotherapy.
For: Prostatic NeoplasmsUnited States · Austria · Belgium - Active not recruitingPHASE3
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
This study looks at a new treatment called 177Lu-PSMA-617 for men with advanced prostate cancer that has spread. It compares this new treatment alongside standard care to standard care alone, aiming to see if it helps patients live longer without their cancer getting worse.
For: Prostatic NeoplasmsUnited States · Austria · Belgium - Active not recruitingPHASE1, PHASE2
Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT
This study looked at a new drug, 225Ac-PSMA-R2, for men with advanced prostate cancer. Researchers wanted to see if it was safe and if it helped fight the cancer. The study has finished enrolling patients.
For: Prostate CancerUnited States · Australia · Canada